Understanding how T and B cells recognize sugars to improve treatments for bacterial diseases
Official title: Molecular basis of glycan recognition by T and B cells
Funded at Scripps Research Institute, the · NIH-11082440 · Data updated 2026-11-12
This study is looking at how certain immune cells in your body recognize sugars from bacteria, with the goal of creating better treatments to help fight serious bacterial infections.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | May 9, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $471,585 |
| NIH project number | 5P01AI172525-03 |
| Project ID | NIH-11082440 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals, particularly children and the elderly, who are at risk for severe bacterial diseases.
✕Less likely to help
Patients with non-bacterial infections or those who do not have a significant immune response to glycan recognition may not benefit from this research.
What this research studies
This research investigates the immune system's recognition of sugars (glycans) by T and B cells, which are crucial for fighting bacterial infections. By studying how these immune cells interact with glycans, the researchers aim to develop new immunotherapy strategies that could enhance the body's ability to respond to severe bacterial diseases. The project involves collaboration between chemists and biologists to create unique immunogens and reagents, allowing for in-depth studies of immune responses and the development of high-affinity antibodies. The findings could lead to optimized treatments that improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new immunotherapy options that significantly improve the treatment of severe bacterial infections.
How similar studies have gone: Previous research has shown promise in using immunotherapy approaches for bacterial infections, suggesting that this line of investigation could yield significant advancements.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Teyton, Luc — Scripps Research Institute, the
- Study coordinator: Teyton, Luc
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.